24295-06-5

Usage

Uses

Used in Flavoring Agents:
2-(2-Methyl-1,3-dioxolan-2-yl)thiazole is used as a flavoring agent in the food industry due to its aromatic properties. Its ability to impart distinctive flavors and scents to food products makes it a valuable ingredient in enhancing the sensory experience of consumers.
Used in Natural Products:
2-(2-Methyl-1,3-dioxolan-2-yl)thiazole is also found in some natural products, indicating its potential use in the development of novel products derived from natural sources. Its presence in these products may contribute to their unique characteristics and benefits.
Used in Pharmaceutical Research:
2-(2-Methyl-1,3-dioxolan-2-yl)thiazole is used as a subject of pharmaceutical research for its potential biological activities, such as antimicrobial and anti-inflammatory properties. Its unique structure and these potential applications make it a promising candidate for the development of new drugs and therapies.
Used in Chemical Research and Development:
2-(2-Methyl-1,3-dioxolan-2-yl)thiazole's diverse potential applications also make it an interesting target for further research and development in the chemical industry. Its unique structure may lead to the discovery of new chemical reactions, synthesis methods, or applications in various fields, including materials science, agriculture, and environmental science.

Upstream product

• 24295-03-2 2-Acetylthiazole 
• 107-21-1 ethylene glycol 

Downstream Products

• 502627-91-0 [2-(2-methyl-1,3-dioxolan-2-yl)-1,3-thiazol-5-yl](phenyl)methanone 
• 774230-98-7 1-(5-bromo-1,3-thiazol-2-yl)ethanone 
• 98025-45-7 2-[1-(hydroxyimino)ethyl]-thiazole 

Relevant academic research and scientific papers

Asymmetric synthesis of (1R,sS,3R)-2-acetyl-5-(1,2,3,4-tetrahydroxybutyl)thiazole

A method for preparing the thiazole analogue 2 of the biologically active compound (1R,2S,3R)-2-acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)imidazole 1 is reported.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.